Orion (ORINY) receives exclusive licence to commercialise Amneal’s (AMRX) generic products in Europe, Australia and New Zealand. Orion announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amneal’s generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialise and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years. Orion and Amneal will work together to develop and register products to Orion markets.
Published first on TheFly
